Mirum Pharmaceuticals Enters Agreement To Acquire Bile Acid Product Portfolio For The Treatment Of Rare Liver Diseases From Travere Therapeutics For $445M
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals has agreed to acquire Travere Therapeutics' bile acid product portfolio for $445 million. The deal includes all rights and assets related to Cholbam® and Chenodal®. Travere will receive $210 million upfront and up to $235 million in potential sales-based milestones. Mirum will fund the upfront payment through a concurrent private placement of $210 million. The acquisition expands Mirum's leadership in rare liver disease treatment and advances Travere's strategy to deliver new treatment standards from its pipeline of innovative medicines for rare diseases.
July 17, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The acquisition of Travere's bile acid product portfolio expands Mirum's leadership in rare liver disease treatment and provides a near-term Phase 3 label expansion opportunity.
The acquisition of Travere's bile acid product portfolio not only expands Mirum's product offerings but also provides a near-term Phase 3 label expansion opportunity. This could potentially increase Mirum's market share and revenues in the future, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Travere will receive up to $445 million from the sale of its bile acid product portfolio to Mirum, strengthening its financial foundation.
The sale of its bile acid product portfolio to Mirum will provide Travere with up to $445 million, strengthening its financial foundation. This could potentially be used to fund its pipeline of innovative medicines for rare diseases, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100